RANCHO CUCAMONGA, Calif., Aug. 12, 2014 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (Nasdaq:AMPH) ("Amphastar" or the "Company") today reported results for the second quarter ended June 30, 2014. Net revenues of $49.0 million for the second quarter GAAP net loss of $1.2 million or $0.03 per
RANCHO CUCAMONGA, Calif., Aug. 5, 2014 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (Nasdaq:AMPH) announced that the Company will release results for its second quarter of 2014 ended June 30, 2014, after the market closes on Tuesday, August 12, 2014, and will hold a conference call to
RANCHO CUCAMONGA, Calif. , June 30, 2014 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (Amphastar) (Nasdaq:AMPH), a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable and
RANCHO CUCAMONGA, Calif., June 25, 2014 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (Amphastar) (Nasdaq:AMPH), a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable and
